Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

Tolazamide

Known as: N-(P-Toluenesulfonyl)-n'-hexamethyleniminourea, Tolazamidum, 1-(hexahydro-1-Azepinyl)-3-P-tolylsulfonylurea 
An intermediate-acting, first-generation sulfonylurea with hypoglycemic activity. Tolazamide is converted into five major metabolites that are… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
1996
Highly Cited
1996
OBJECTIVE: To compare the risk of serious hypoglycemia associated with the use of individual sulfonylureas in older people. 
Highly Cited
1992
Highly Cited
1992
IN 1984, Congress enacted a new law that greatly affected the economics of the pharmaceutical industry in the United States. It… 
Review
1991
Review
1991
SummaryThe article reviews the effect of diabetes on the pharmacokinetics and pharmacodynamics of drugs in humans.For most drugs… 
Highly Cited
1988
Highly Cited
1988
Specific, high affinity sulfonylurea receptors were characterized on membranes of an insulin-secreting hamster beta cell line… 
Highly Cited
1986
Highly Cited
1986
To determine whether sulfonylureas and exogenous insulin have different effects on insulin action, we studied eight patients with… 
Review
1981
Review
1981
In this report we review the pharmacology of the hypoglycemic sulfonylurea drugs. The early work with sulfonylureas is briefly… 
Highly Cited
1981
Highly Cited
1981
The mechanism(s) by which the oral sulfonylurea, tolazamide, exerts its extrapancreatic hypoglycemic effects was studied using… 
  • figure 1
  • figure 3
  • figure 2
  • figure 4
1980
1980
Granulocyte adherence in 10 of 15 untreated asymptomatic hyperglycemic diabetic outpatients (mean fasting glucose ± SEM, 289 ± 16… 
  • table 1
Highly Cited
1980
Highly Cited
1980
Abstract Several drugs and related compounds which are secondary and tertiary amines were tested for mutagenicity with the Ames… 
1956
1956
Summary Oral administration of 100 mg 1-3-butyl-p-tolylsulfonylurea per kg body weight to normal rats results in a marked… 
  • figure 1